These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 19175524)

  • 1. BI-69A11-mediated inhibition of AKT leads to effective regression of xenograft melanoma.
    Gaitonde S; De SK; Tcherpakov M; Dewing A; Yuan H; Riel-Mehan M; Krajewski S; Robertson G; Pellecchia M; Ronai Z
    Pigment Cell Melanoma Res; 2009 Apr; 22(2):187-95. PubMed ID: 19175524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effective inhibition of melanoma by BI-69A11 is mediated by dual targeting of the AKT and NF-κB pathways.
    Feng Y; Barile E; De SK; Stebbins JL; Cortez A; Aza-Blanc P; Villanueva J; Heryln M; Krajewski S; Pellecchia M; Ronai ZA; Chiang GG
    Pigment Cell Melanoma Res; 2011 Aug; 24(4):703-13. PubMed ID: 21592316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of melanoma development in the Nras((Q61K)) ::Ink4a(-/-) mouse model by the small molecule BI-69A11.
    Feng Y; Lau E; Scortegagna M; Ruller C; De SK; Barile E; Krajewski S; Aza-Blanc P; Williams R; Pinkerton AB; Jackson M; Chin L; Pellecchia M; Bosenberg M; Ronai ZA
    Pigment Cell Melanoma Res; 2013 Jan; 26(1):136-42. PubMed ID: 23035722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blockade of autophagy enhances proapoptotic potential of BI-69A11, a novel Akt inhibitor, in colon carcinoma.
    Pal I; Parida S; Prashanth Kumar BN; Banik P; Kumar Dey K; Chakraborty S; Bhutia SK; Mandal M
    Eur J Pharmacol; 2015 Oct; 765():217-27. PubMed ID: 26306675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BI-69A11 enhances susceptibility of colon cancer cells to mda-7/IL-24-induced growth inhibition by targeting Akt.
    Pal I; Sarkar S; Rajput S; Dey KK; Chakraborty S; Dash R; Das SK; Sarkar D; Barile E; De SK; Pellecchia M; Fisher PB; Mandal M
    Br J Cancer; 2014 Jul; 111(1):101-11. PubMed ID: 24892445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and SAR studies of dual AKT/NF-κB inhibitors against melanoma.
    Barile E; De SK; Feng Y; Chen V; Yang L; Ronai Z; Pellecchia M
    Chem Biol Drug Des; 2013 Nov; 82(5):520-533. PubMed ID: 23790042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of epithelial to mesenchymal transition in colorectal carcinoma by regulation of the E-cadherin-β-catenin-vinculin axis.
    Pal I; Rajesh Y; Banik P; Dey G; Dey KK; Bharti R; Naskar D; Chakraborty S; Ghosh SK; Das SK; Emdad L; Kundu SC; Fisher PB; Mandal M
    Cancer Lett; 2019 Jun; 452():254-263. PubMed ID: 30904616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. R115777 (Zarnestra)/Zoledronic acid (Zometa) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl-2 and bad phosphorylation.
    Caraglia M; Marra M; Leonetti C; Meo G; D'Alessandro AM; Baldi A; Santini D; Tonini G; Bertieri R; Zupi G; Budillon A; Abbruzzese A
    J Cell Physiol; 2007 May; 211(2):533-43. PubMed ID: 17192846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Small molecule inhibition of polo-like kinase 1 by volasertib (BI 6727) causes significant melanoma growth delay and regression in vivo.
    Cholewa BD; Ndiaye MA; Huang W; Liu X; Ahmad N
    Cancer Lett; 2017 Jan; 385():179-187. PubMed ID: 27793694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simultaneous targeting of COX-2 and AKT using selenocoxib-1-GSH to inhibit melanoma.
    Gowda R; Madhunapantula SV; Desai D; Amin S; Robertson GP
    Mol Cancer Ther; 2013 Jan; 12(1):3-15. PubMed ID: 23112250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
    Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA
    Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anticancer efficacy of simvastatin on prostate cancer cells and tumor xenografts is associated with inhibition of Akt and reduced prostate-specific antigen expression.
    Kochuparambil ST; Al-Husein B; Goc A; Soliman S; Somanath PR
    J Pharmacol Exp Ther; 2011 Feb; 336(2):496-505. PubMed ID: 21059805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ferulic Acid Exerts Anti-Angiogenic and Anti-Tumor Activity by Targeting Fibroblast Growth Factor Receptor 1-Mediated Angiogenesis.
    Yang GW; Jiang JS; Lu WQ
    Int J Mol Sci; 2015 Oct; 16(10):24011-31. PubMed ID: 26473837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effective targeting of triple-negative breast cancer cells by PF-4942847, a novel oral inhibitor of Hsp 90.
    Mehta PP; Whalen P; Baxi SM; Kung PP; Yamazaki S; Yin MJ
    Clin Cancer Res; 2011 Aug; 17(16):5432-42. PubMed ID: 21715568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repurposing the serotonin agonist Tegaserod as an anticancer agent in melanoma: molecular mechanisms and clinical implications.
    Liu W; Stachura P; Xu HC; Umesh Ganesh N; Cox F; Wang R; Lang KS; Gopalakrishnan J; Häussinger D; Homey B; Lang PA; Pandyra AA
    J Exp Clin Cancer Res; 2020 Feb; 39(1):38. PubMed ID: 32085796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and Evaluation of the Tumor Cell Growth Inhibitory Potential of New Putative HSP90 Inhibitors.
    Bizarro A; Sousa D; Lima RT; Musso L; Cincinelli R; Zuco V; De Cesare M; Dallavalle S; Vasconcelos MH
    Molecules; 2018 Feb; 23(2):. PubMed ID: 29438315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 2-Arylthiazolidine-4-carboxylic acid amides (ATCAA) target dual pathways in cancer cells: 5'-AMP-activated protein kinase (AMPK)/mTOR and PI3K/Akt/mTOR pathways.
    Li CM; Narayanan R; Lu Y; Hurh E; Coss CC; Barrett CM; Miller DD; Dalton JT
    Int J Oncol; 2010 Oct; 37(4):1023-30. PubMed ID: 20811725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting activated Akt with GDC-0068, a novel selective Akt inhibitor that is efficacious in multiple tumor models.
    Lin J; Sampath D; Nannini MA; Lee BB; Degtyarev M; Oeh J; Savage H; Guan Z; Hong R; Kassees R; Lee LB; Risom T; Gross S; Liederer BM; Koeppen H; Skelton NJ; Wallin JJ; Belvin M; Punnoose E; Friedman LS; Lin K
    Clin Cancer Res; 2013 Apr; 19(7):1760-72. PubMed ID: 23287563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tirucallic acids are novel pleckstrin homology domain-dependent Akt inhibitors inducing apoptosis in prostate cancer cells.
    Estrada AC; Syrovets T; Pitterle K; Lunov O; Büchele B; Schimana-Pfeifer J; Schmidt T; Morad SA; Simmet T
    Mol Pharmacol; 2010 Mar; 77(3):378-87. PubMed ID: 20018812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic anticancer efficacy of MEK inhibition and dual PI3K/mTOR inhibition in castration-resistant prostate cancer.
    Park H; Kim Y; Sul JW; Jeong IG; Yi HJ; Ahn JB; Kang JS; Yun J; Hwang JJ; Kim CS
    Prostate; 2015 Nov; 75(15):1747-59. PubMed ID: 26250606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.